Phathom Pharmaceuticals Inc

NASDAQ:PHAT  
10.56
-1.55 (-12.80%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)413.69M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.33 Million
Adjusted EPS-$1.24
See more estimates
10-Day MA$10.46
50-Day MA$8.91
200-Day MA$13.98
See more pivots

Phathom Pharmaceuticals Inc Stock, NASDAQ:PHAT

100 Campus Drive, Suite 102, Florham Park, New Jersey 07932
United States of America
Phone: +1.877.742.8466
Number of Employees: 77

Description

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. Its product candidate vonoprazan is an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.